Pharmacokinetics of incretin mimetics: a forward-looking perspective

The development of incretin mimetic drug therapy has significantly advanced over the past two decades since the approval of the first GLP-1 receptor agonist in 2005. In this presentation, we will delve into the critical pharmacokinetic features that are pivotal in shaping the future of incretin mimetics. We will explore the relevance of the four pillars of pharmacokinetics—absorption, distribution, metabolism, and excretion—in addressing the challenges associated with incretin mimetic drug development. Additionally, we will present examples of how modeling and simulation can enhance our understanding and help overcome these challenges, covering topics such as formulations (biologics, small molecules), routes of administration (subcutaneous, oral), dosing frequency, and allometry in dynamic conditions.